Core Insights - Advanced Biomed Inc. has launched the A+PerfusC system, a compact 3D cell culture incubator designed to replicate human physiological conditions in vitro [1][2] - The A+PerfusC platform integrates automated perfusion with environmental control, allowing for up to 12 days of continuous, hands-free culture, which enhances cell viability and drug response predictability [2][5] - The global 3D cell culture market is projected to grow from USD 2.32 billion in 2025 to over USD 4.71 billion by 2030, with a compound annual growth rate of over 15.6% [4] Company Overview - Advanced Biomed Inc. specializes in innovative biomedical technologies for cancer detection and precision medicine, operating through subsidiaries in Taiwan, Hong Kong, and Mainland China [9][10] - The company has developed a proprietary microfluidic platform for advanced circulating tumor cell detection, with regulatory clearances in progress in China and plans for global expansion [10] Product Features - The A+PerfusC system supports up to 8 independent channels per plate, allowing for 600 tumor spheroids per row and a total of 4,800 tumor spheroids per plate [8] - The system is designed for easy transfer into 96 or 384 well plates for high-throughput drug screening and can be mounted on microscopy platforms [8] Future Plans - The company plans to scale up the A+PerfusC system for high-throughput use and integrate imaging with AI-driven analytics to enhance tumor profiling and personalized treatment development [5]